Literature DB >> 10722712

Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2.

Y C Choi1, G T Park, T S Kim, I N Sunwoo, P M Steinert, S Y Kim.   

Abstract

Sporadic inclusion body myositis (SIBM) is characterized by vacuolar degeneration of muscle fibers and intrafiber clusters of paired helical filaments with abnormal amyloid deposition. Because of their potential involvement in other degenerative disorders, we have examined the expression of transglutaminases (TGases) in normal and SIBM tissues. We report that at least two different enzymes, the ubiquitous TGase 2 as well as the TGase 1 enzyme, are present in muscle tissues. However, in comparison with normal tissue, the expression of TGases 1 and 2 was increased 2.5- and 4-fold in SIBM, accompanied by about a 20-fold higher total TGase activity. By immunohistochemical staining, in normal muscle, TGase 2 expression was restricted to some endomysial connective tissue elements, whereas TGase 1 and beta-amyloid proteins were not detectable. In SIBM muscle, both TGases 1 and 2 as well as amyloid proteins were brightly expressed and co-localized in the vacuolated muscle fibers, but none of these proteins colocalized with inflammatory cell markers. Next, we isolated high molecular weight insoluble proteins from SIBM muscle tissue and showed that they were cross-linked by about 6 residues/1000 residues of the isopeptide bond. Furthermore, by amino acid sequencing of solubilized tryptic peptides, they contain amyloid and skeletal muscle proteins. Together, these findings suggest that elevated expression of TGases 1 and 2 participate in the formation of insoluble amyloid deposits in SIBM tissue and in this way may contribute to progressive and debilitating muscle disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722712     DOI: 10.1074/jbc.275.12.8703

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

Review 1.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

2.  Screening for transglutaminase-catalyzed modifications by peptide mass finger printing using multipoint recalibration on recognized peaks for high mass accuracy.

Authors:  Cecilia Sundby Emanuelsson; Sandor Boros; Karin Hjernoe; Wilbert C Boelens; Peter Hojrup
Journal:  J Biomol Tech       Date:  2005-09

3.  Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis.

Authors:  Kenneth C Parker; Sek Won Kong; Ronan J Walsh; Mohammad Salajegheh; Behzad Moghadaszadeh; Anthony A Amato; Remedios Nazareno; Yin Yin Lin; Bryan Krastins; David A Sarracino; Alan H Beggs; Jack L Pinkus; Steven A Greenberg
Journal:  Muscle Nerve       Date:  2009-06       Impact factor: 3.217

4.  Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions changes structure for activation.

Authors:  Bijan Ahvazi; Hee Chul Kim; Sun-Ho Kee; Zoltan Nemes; Peter M Steinert
Journal:  EMBO J       Date:  2002-05-01       Impact factor: 11.598

5.  Clinical and pathological characteristics of four Korean patients with limb-girdle muscular dystrophy type 2B.

Authors:  Seung-Hun Oh; Seong-Woong Kang; Jin-Goo Lee; Sang-Jun Na; Tai-Seung Kim; Young-Chul Choi
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

6.  A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor.

Authors:  Joonhong Sohn; Ju Byung Chae; Sun Young Lee; Soo-Youl Kim; June-Gone Kim
Journal:  Korean J Ophthalmol       Date:  2010-02-05

Review 7.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

8.  Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis.

Authors:  Joonhong Sohn; Tae-Im Kim; Young-Hee Yoon; Joo-Yong Kim; Soo-Youl Kim
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Gender dimorphic formation of mouse Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress.

Authors:  Shinichiro Hanada; Natasha T Snider; Elizabeth M Brunt; Paul F Hollenberg; M Bishr Omary
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.